HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bakker, W. H. Articles by Lamberts, S. W. Search for Related Content PubMed PubMed Citation Articles by Bakker, W. H. Articles by Lamberts, S. W.

Receptor Scintigraphy with a Radioiodinated Somatostatin Analogue: Radiolabeling, Purification, Biologic Activity, and In Vivo Application in Animals

Departments of Nuclear Medicine and Internal Medicine III, University Hospital Dijkzigt and Erasmus University Medical School, Rotterdam, The Netherlands; Division of Endocrine Oncology, Dr. Daniel den Hoed Cancer Centre, Rotterdam, The Netherlands; and Sandoz Research Institute, Berne, Switzerland

Correspondence: For reprints contact: Willem H. Bakker, University Hospital Dijkzigt. Department of Nuclear Medicine, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands.

ABSTRACT

Radioiodinated Tyr-3-octreotide, a somatostatin analogue, is a useful ligand for the in vitro detection of somatostatin receptors. In this study, we have investigated the possible in vivo application of this radioligand in the detection of somatostatin receptor-bearing tumors by scintigraphy. The specific somatostatin-like biologic activity of radioiodinated Tyr-3-octreotide was confirmed in vitro: (a) radioiodinated Tyr-3-octreotide competes in the nanomolar range with specific receptor binding of somatostatin to suspended human meningioma membranes and (b) the secretion of growth hormone by cultured rat pituitary cells was similarly inhibited by iodinated Tyr-3-octreotide and somatostatin. In rats,intravenously injected ¹²³I-Tyr-3-octreotide is rapidly cleared from the circulation mainly by the liver. Although this rapid clearance limits the amount of tracer available for somatostatin receptor-bearing tumors, the advantage of this rapid clearance is that the background level is rapidly reduced in favor of scintigraphic imaging of these tumors. Pancreatic tumors in rats were localized by scintigraphy after intravenous injection of ¹²³I-Tyr-3-octreotide.

This article has been cited by other articles:

				G. Khanna, D. Bushnell, and M. S. O'Dorisio Utility of Radiolabeled Somatostatin Receptor Analogues for Staging/Restaging and Treatment of Somatostatin Receptor-Positive Pediatric Tumors Oncologist, April 1, 2008; 13(4): 382 - 389. [Abstract] [Full Text] [PDF]

				M. de Visser, W. M. van Weerden, C. M.A. de Ridder, S. Reneman, M. Melis, E. P. Krenning, and M. de Jong Androgen-Dependent Expression of the Gastrin-Releasing Peptide Receptor in Human Prostate Tumor Xenografts J. Nucl. Med., January 1, 2007; 48(1): 88 - 93. [Abstract] [Full Text] [PDF]

				M. Duran-Prado, C. Bucharles, B. J. Gonzalez, R. Vazquez-Martinez, A. J. Martinez-Fuentes, S. Garcia-Navarro, S. J. Rhodes, H. Vaudry, M. M. Malagon, and J. P. Castano Porcine Somatostatin Receptor 2 Displays Typical Pharmacological sst2 Features but Unique Dynamics of Homodimerization and Internalization Endocrinology, January 1, 2007; 148(1): 411 - 421. [Abstract] [Full Text] [PDF]

				A. Capello, E. P. Krenning, B. F. Bernard, W. A.P. Breeman, J. L. Erion, and M. de Jong Anticancer Activity of Targeted Proapoptotic Peptides J. Nucl. Med., January 1, 2006; 47(1): 122 - 129. [Abstract] [Full Text] [PDF]

				J. van der Hoek, M. Waaijers, P. M. van Koetsveld, D. Sprij-Mooij, R. A. Feelders, H. A. Schmid, P. Schoeffter, D. Hoyer, D. Cervia, J. E. Taylor, et al. Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells Am J Physiol Endocrinol Metab, August 1, 2005; 289(2): E278 - E287. [Abstract] [Full Text] [PDF]

				Z. Cheng, J. Chen, T. P. Quinn, and S. S. Jurisson Radioiodination of Rhenium Cyclized {alpha}-Melanocyte-Stimulating Hormone Resulting in Enhanced Radioactivity Localization and Retention in Melanoma Cancer Res., February 15, 2004; 64(4): 1411 - 1418. [Abstract] [Full Text] [PDF]

				M. Lubberink, V. Tolmachev, C. Widstrom, A. Bruskin, H. Lundqvist, and J.-E. Westlin 110mIn-DTPA-D-Phe1-Octreotide for Imaging of Neuroendocrine Tumors with PET J. Nucl. Med., October 1, 2002; 43(10): 1391 - 1397. [Abstract] [Full Text] [PDF]

				G. Bussolati, M. Chinol, B. Chini, A. Nacca, P. Cassoni, and G. Paganelli 111In-labeled 1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic Acid-Lys8-Vasotocin: A New Powerful Radioligand for Oxytocin Receptor-expressing Tumors Cancer Res., June 1, 2001; 61(11): 4393 - 4397. [Abstract] [Full Text] [PDF]